Merck & Company Inc. (new)

76.27+0.1300+0.17%Vol 13.91M1Y Perf -1.38%
Jun 11th, 2021 16:02 DELAYED
BID76.26 ASK76.48
Open76.71 Previous Close76.14
Pre-Market- After-Market76.41
 - -  0.14 0.18%
Target Price
93.40 
Analyst Rating
Strong Buy 1.50
Potential %
22.46 
Finscreener Ranking
★★★     49.65
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★+     53.53
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★+     56.35
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
★★+     43.52
Market Cap193.12B 
Earnings Rating
Buy
Price Range Ratio 52W %
28.34 
Earnings Date
30th Jul 2021

Today's Price Range

75.6076.86

52W Range

71.7187.80

5 Year PE Ratio Range

17.1092.20

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
2.91%
1 Month
-2.22%
3 Months
2.24%
6 Months
-8.06%
1 Year
-1.38%
3 Years
22.15%
5 Years
36.34%
10 Years
154.17%

TickerPriceChg.Chg.%
MRK76.270.13000.17
AAPL127.351.24000.98
GOOG2 513.93-7.6700-0.30
MSFT257.890.65000.25
XOM62.17-0.5800-0.92
WFC45.680.59001.31
JNJ164.96-2.1200-1.27
FB331.26-1.2000-0.36
GE13.690.06000.44
JPM160.29-0.1100-0.07
Financial StrengthValueIndustryS&P 500US Markets
0.60
1.00
0.47
1.16
11.30
Leverage Ratio 3.30
ProfitabilityValueIndustryS&P 500US Markets
67.00
19.20
27.00
11.40
14.81
RevenueValueIndustryS&P 500US Markets
48.02B
18.96
5.44
4.43
DividendsValueIndustryS&P 500US Markets
3.57
2.60
9.09
6.64
Payout ratio89.00
Earnings HistoryEstimateReportedSurprise %
Q01 20211.631.40-14.11
Q04 20201.361.32-2.94
Q03 20201.441.7420.83
Q02 20201.141.3720.18
Q01 20201.391.507.91
Q04 20191.141.161.75
Q03 20191.251.5120.80
Q02 20191.161.3012.07
Earnings Per EndEstimateRevision %Trend
6/2021 QR1.664.40Positive
9/2021 QR1.65-5.71Negative
12/2021 FY6.47-1.37Negative
12/2022 FY6.83-2.01Negative
Next Report Date30th Jul 2021
Estimated EPS Next Report1.58
Estimates Count5
EPS Growth Next 5 Years %6.10
Volume Overview
Volume13.91M
Shares Outstanding2.53B
Trades Count99.15K
Dollar Volume1.07B
Avg. Volume11.89M
Avg. Weekly Volume13.70M
Avg. Monthly Volume11.93M
Avg. Quarterly Volume12.40M

Merck & Company Inc. (new) (NYSE: MRK) stock closed at 76.27 per share at the end of the most recent trading day (a 0.17% change compared to the prior day closing price) with a volume of 13.93M shares and market capitalization of 193.12B. Is a component of S&P 500, Dow Jones 30, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 74000 people. Merck & Company Inc. (new) CEO is Kenneth C. Frazier.

The one-year performance of Merck & Company Inc. (new) stock is -1.38%, while year-to-date (YTD) performance is -6.76%. MRK stock has a five-year performance of 36.34%. Its 52-week range is between 71.71 and 87.8, which gives MRK stock a 52-week price range ratio of 28.34%

Merck & Company Inc. (new) currently has a PE ratio of 26.90, a price-to-book (PB) ratio of 6.96, a price-to-sale (PS) ratio of 3.84, a price to cashflow ratio of 16.60, a PEG ratio of 2.32, a ROA of 7.76%, a ROC of 13.66% and a ROE of 25.64%. The company’s profit margin is 14.81%, its EBITDA margin is 27.00%, and its revenue ttm is $48.02 Billion , which makes it $18.96 revenue per share.

Of the last four earnings reports from Merck & Company Inc. (new), there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $1.58 for the next earnings report. Merck & Company Inc. (new)’s next earnings report date is 30th Jul 2021.

The consensus rating of Wall Street analysts for Merck & Company Inc. (new) is Strong Buy (1.5), with a target price of $93.4, which is +22.46% compared to the current price. The earnings rating for Merck & Company Inc. (new) stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Merck & Company Inc. (new) has a dividend yield of 3.57% with a dividend per share of $2.60 and a payout ratio of 89.00%.

Merck & Company Inc. (new) has a Neutral technical analysis rating based on Technical Indicators (ADX : 13.39, ATR14 : 5.72, CCI20 : -424.75, Chaikin Money Flow : -0.13, MACD : -0.74, Money Flow Index : 28.49, ROC : -1.59, RSI : 50.41, STOCH (14,3) : 94.75, STOCH RSI : 1.00, UO : 88.39, Williams %R : -5.25), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Merck & Company Inc. (new) in the last 12-months were: Caroline Litchfield (Option Excercise at a value of $197 398), David Michael Williams (Option Excercise at a value of $104 098), Dean Y. Li (Option Excercise at a value of $185 340), Frank Clyburn (Option Excercise at a value of $636 757), Frank Clyburn (Sold 57 076 shares of value $4 591 986 ), Jennifer Zachary (Option Excercise at a value of $438 557), Julie L. Gerberding (Option Excercise at a value of $0), Julie L. Gerberding (Sold 36 285 shares of value $2 902 976 ), Kenneth C. Frazier (Sold 560 000 shares of value $45 594 022 ), Lisa LeCointe-Cephas (Option Excercise at a value of $131 626), Michael J. Mcnally (Option Excercise at a value of $173 560), Rita A. Karachun (Option Excercise at a value of $224 400), Robert M. Davis (Option Excercise at a value of $0), Robert M. Davis (Sold 502 546 shares of value $40 720 648 ), Sanat Chattopadhyay (Sold 10 380 shares of value $861 676 ), Steven C. Mizell (Option Excercise at a value of $347 121)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
9 (75.00 %)
10 (76.92 %)
8 (72.73 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (25.00 %)
3 (23.08 %)
3 (27.27 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.50
Strong Buy
1.46
Moderate Buy
1.55

Merck & Company Inc. (new)

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, close to 40% of the firm's sales are generated in the United States.

CEO: Kenneth C. Frazier

Telephone: +1 908 740-4000

Address: 2000 Galloping Hill Road, Kenilworth 07033, NJ, US

Number of employees: 74 000

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

64%36%

Bearish Bullish

66%34%

Bearish Bullish

57%43%

News

Stocktwits